Results 141 to 150 of about 11,328,563 (174)

Amyloid-Related Imaging Abnormality (ARIA) Beyond the APOE-ε4 Allele [PDF]

Chronic Diseases and Translational Medicine
ABSTRACTMonoclonal antibodies (mAbs) have made significant progress in the treatment of Alzheimer's disease (AD). However, mAbs are associated with adverse effects, including Amyloid‐Related Imaging Abnormality (ARIA), which manifests as edema or effusion (ARIA‐E) and hemorrhage (ARIA‐H). The mechanisms behind these effects are not yet fully understood.
Sulistyo Emantoko Dwi Putra, Paulus Anam Ong, Ratih Asmana Ningrum   +2 more
exaly   +5 more sources

Spontaneous ARIA (Amyloid-Related Imaging Abnormalities) and Cerebral Amyloid Angiopathy Related Inflammation in Presenilin 1-Associated Familial Alzheimer's Disease [PDF]

Journal of Alzheimer's Disease, 2015
Amyloid-related imaging abnormalities (ARIA), thought to reflect immune responses to vascular amyloid, have been detected in several amyloid-modifying therapy trials for Alzheimer's disease (AD). We report a case of ARIA developing spontaneously during the course of Presenilin 1 (PSEN1)-associated familial AD (FAD), in an APOE4 homozygous patient ...
Tammaryn Lashley, Huw Morris, Nick C. Fox   +2 more
exaly   +6 more sources

Are We Ready for Amyloid-Related Imaging Abnormalities (ARIA) Monitoring? A European Survey Among Neuroradiologists and Neurologists by the ESNR/EAN Working Group

European Radiology
Objectives Amyloid-lowering immunotherapies can cause amyloid-related imaging abnormalities (ARIA), requiring brain MRI for detection and monitoring. The European Society of Neuroradiology (ESNR)/European Academy of Neurology (EAN) ARIA Working Group conducted a survey to assess European clinicians' readiness for this logistical challenge and need for ...
Roland Wiest, Giovanni B Frisoni, Tiago Gil Oliveira   +2 more
exaly   +7 more sources

Monitoring of Amyloid Related Imaging Abnormalities: SWI vs T2*-GRE

journal of prevention of Alzheimer's disease, The
Amyloid-β-directed monoclonal antibody therapies may lead to amyloid-related imaging abnormalities (ARIA). Clinical trials that formed the basis for the ARIA radiographic severity grading scale adopted by the approved drugs' labels utilized T2* gradient ...
Jeffrey L. Cummings, Diana M Sima, Philip Scheltens   +2 more
exaly   +4 more sources

Some of the next articles are maybe not open access.

Related searches:

Imaging of Amyloid-Related Imaging Abnormalities (ARIA)

RöFo - Fortschritte auf dem Gebiet der Röntgenstrahlen und der bildgebenden Verfahren, 2023
Patients with Alzheimer’s disease (AD) can now be treated with monoclonal antibodies aiming at clearing amyloid plaques from the brain parenchyma. Weeks after initiation of this drug therapy, patients may develop so-called amyloid-related imaging abnormalities (ARIA) on MRI. ARIA comprise vasogenic edema and leptomeningeal effusions (ARIA-E) as well as
Horst Urbach, Jennifer Linn, Elke Hattingen, Jochen Fiebach   +3 more
openaire   +2 more sources

Validation of an MRI Rating Scale for Amyloid-Related Imaging Abnormalities [PDF]

Journal of Neuroimaging, 2017
INTRODUCTION: Immunotherapeutic agents against amyloid beta (Aβ) are associated with adverse events, including amyloid-related imaging abnormalities with edema and effusion (ARIA-E). Recently, a magnetic resonance imaging (MRI) rating scale was developed
Mike P. Wattjes, Marita Daams, Frederik Barkhof   +2 more
exaly   +1 more source

A standardized protocol for detection of Amyloid Related Imaging Abnormality (ARIA) on 3T Philips Magnetic Resonance Imaging (MRI)

Alzheimer's & Dementia, 2022
AbstractBackgroundARIA is a common side effect of aducanumab, the first anti‐amyloid pharmacotherapy approved by the US Food and Drug Administration (FDA) to treat Alzheimer’s disease. Regular MRI is required by FDA to detect and monitor different forms of ARIA during initiation of therapy.
Nandor K Pinter, Sandeep Ganji, Brian Johnson, Willem Huijbers, Bela Ajtai, Ryu Dorn, Baraa Alnaji, Sarah Harlock, Erica Westphal, Harry Friel, Laszlo Mechtler   +10 more
openaire   +1 more source

Amyloid-Related Imaging Abnormalities (ARIA) in Immunotherapy Trials for Alzheimer’s Disease: Need for Prognostic Biomarkers?

Journal of Alzheimer's Disease, 2016
At the 8th International Conference on Clinical Trials in Alzheimer’s Disease held November 5–7, 2015 in Barcelona, Spain, promising data were presented on two candidate Alzheimer’s disease immunotherapeutic agents, gantenerumab and aducanumab. Trial results demonstrated that the implementation of cerebrospinal fluid and Aβ-PET biomarkers improves ...
Fabrizio, Piazza, Bengt, Winblad
openaire   +2 more sources

AI-Assisted Detection of Amyloid-Related Imaging Abnormalities (ARIA): Promise and Pitfalls

American Journal of Neuroradiology
Jeffrey Petrella, P Murali Doraiswamy
exaly   +2 more sources